118 related articles for article (PubMed ID: 8700151)
41. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor.
Stables J; Green A; Marshall F; Fraser N; Knight E; Sautel M; Milligan G; Lee M; Rees S
Anal Biochem; 1997 Oct; 252(1):115-26. PubMed ID: 9324949
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin.
Mancini F; Toro CM; Mabilia M; Giannangeli M; Pinza M; Milanese C
Biochem Pharmacol; 1999 Sep; 58(5):851-9. PubMed ID: 10449196
[TBL] [Abstract][Full Text] [Related]
43. Antiangiogenic and antiproliferative activity of suramin analogues.
Gagliardi AR; Kassack M; Kreimeyer A; Muller G; Nickel P; Collins DC
Cancer Chemother Pharmacol; 1998; 41(2):117-24. PubMed ID: 9443624
[TBL] [Abstract][Full Text] [Related]
44. Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors.
Klapperstück M; Büttner C; Nickel P; Schmalzing G; Lambrecht G; Markwardt F
Eur J Pharmacol; 2000 Jan; 387(3):245-52. PubMed ID: 10650169
[TBL] [Abstract][Full Text] [Related]
45. Role of the prenyl group on the G protein gamma subunit in coupling trimeric G proteins to A1 adenosine receptors.
Yasuda H; Lindorfer MA; Woodfork KA; Fletcher JE; Garrison JC
J Biol Chem; 1996 Aug; 271(31):18588-95. PubMed ID: 8702509
[TBL] [Abstract][Full Text] [Related]
46. Phosphoinositide 3-kinase-dependent antagonism in mammalian olfactory receptor neurons.
Ukhanov K; Brunert D; Corey EA; Ache BW
J Neurosci; 2011 Jan; 31(1):273-80. PubMed ID: 21209212
[TBL] [Abstract][Full Text] [Related]
47. Diimidazo[1,2-c:4',5'-e]pyrimidines: adenosine agonist activity demonstrated by microphysiometry.
Camp D; Green JM; Kaiser SM; Moni RW; Townsend-Nicholson A; Schofield PR; Quinn RJ
Bioorg Med Chem Lett; 1998 Mar; 8(6):691-4. PubMed ID: 9871584
[TBL] [Abstract][Full Text] [Related]
48. The Gαi-GIV binding interface is a druggable protein-protein interaction.
DiGiacomo V; de Opakua AI; Papakonstantinou MP; Nguyen LT; Merino N; Blanco-Canosa JB; Blanco FJ; Garcia-Marcos M
Sci Rep; 2017 Aug; 7(1):8575. PubMed ID: 28819150
[TBL] [Abstract][Full Text] [Related]
49. Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells.
Hui EK; Nayak DP
J Gen Virol; 2002 Dec; 83(Pt 12):3055-3066. PubMed ID: 12466482
[TBL] [Abstract][Full Text] [Related]
50. G protein antagonists.
Freissmuth M; Waldhoer M; Bofill-Cardona E; Nanoff C
Trends Pharmacol Sci; 1999 Jun; 20(6):237-45. PubMed ID: 10366866
[TBL] [Abstract][Full Text] [Related]
51. Diimidazo[1,2-c:4',5'-e]pyrimidines: N6-N1 conformationally restricted adenosines.
Camp D; Li Y; McCluskey A; Moni RW; Quinn RJ
Bioorg Med Chem Lett; 1998 Mar; 8(6):695-8. PubMed ID: 9871585
[TBL] [Abstract][Full Text] [Related]
52. A small-molecule screen identifies the antitrypanosomal agent suramin and analogues NF023 and NF449 as inhibitors of STAT5a/b.
Berg A; Berg T
Bioorg Med Chem Lett; 2017 Aug; 27(15):3349-3352. PubMed ID: 28624143
[TBL] [Abstract][Full Text] [Related]
53. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
Dhar S; Gullbo J; Csoka K; Eriksson E; Nilsson K; Nickel P; Larsson R; Nygren P
Eur J Cancer; 2000 Apr; 36(6):803-9. PubMed ID: 10762755
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and adenosine receptor affinity of 7-beta-D-ribofuranosylxanthine.
Bridson PK; Lin X; Melman N; Ji XD; Jacobson KA
Nucleosides Nucleotides; 1998 Apr; 17(4):759-68. PubMed ID: 9708335
[TBL] [Abstract][Full Text] [Related]
55. The G-protein G(o) in mammalian cardiac muscle: localization and coupling to A1 adenosine receptors.
Asano T; Shinohara H; Morishita R; Norota I; Kato K; Endoh M
J Biochem; 1995 Jan; 117(1):183-9. PubMed ID: 7775387
[TBL] [Abstract][Full Text] [Related]
56. New sulfonated distamycin A derivatives with bFGF complexing activity.
Ciomei M; Pastori W; Mariani M; Sola F; Grandi M; Mongelli N
Biochem Pharmacol; 1994 Jan; 47(2):295-302. PubMed ID: 7508230
[TBL] [Abstract][Full Text] [Related]
57. Suramin analogues with a 2-phenylbenzimidazole moiety as partial structure; potential anti HIV- and angiostatic drugs, 2: Sulfanilic acid-, benzenedisulfonic acid-, and naphthalenetrisulfonic acid analogues.
Kreimeyer A; Müller G; Kassack M; Nickel P; Gagliardi AR
Arch Pharm (Weinheim); 1998 Mar; 331(3):97-103. PubMed ID: 9557135
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y
Pillaiyar T; Funke M; Al-Hroub H; Weyler S; Ivanova S; Schlegel J; Abdelrahman A; Müller CE
Eur J Med Chem; 2020 Jan; 186():111789. PubMed ID: 31727469
[TBL] [Abstract][Full Text] [Related]
59. The anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA binding protein Mcm10.
Paulson CN; John K; Baxley RM; Kurniawan F; Orellana K; Francis R; Sobeck A; Eichman BF; Chazin WJ; Aihara H; Georg GI; Hawkinson JE; Bielinsky AK
Open Biol; 2019 Aug; 9(8):190117. PubMed ID: 31409229
[TBL] [Abstract][Full Text] [Related]
60. Ligand with Two Modes of Interaction with the Dopamine D
Ågren R; Zeberg H; Stępniewski TM; Free RB; Reilly SW; Luedtke RR; Århem P; Ciruela F; Sibley DR; Mach RH; Selent J; Nilsson J; Sahlholm K
ACS Chem Neurosci; 2020 Oct; 11(19):3130-3143. PubMed ID: 32865974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
